X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Representatives from insulin manufacturers blamed a system that requires them to pay higher and higher rebates to pharmacy-benefit managers to gain access to the patients whose prescriptions the PBMs manage.

Decisions by two of the world’s biggest insulin producers to offer bigger discounts on drugs used by millions of diabetics are raising questions from Congress about whether the companies could have done so sooner.

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.